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ABSTRACT
Introduction: While monotherapy is often 
recommended as initial treatment, most patients 
require dose escalation and add-on agents to 
achieve their blood pressure (BP) goal. This 
secondary analysis evaluated the efficacy and 
safety of initiating patients on a regimen of fixed-
dose amlodipine (AML)/olmesartan medoxomil 
(OM) ± hydrochlorothiazide (HCTZ) who were 
uncontrolled on prior monotherapy with a 
calcium channel blocker (CCB) or angiotensin 
II receptor blocker (ARB). 
Methods: Patients uncontrolled on prior 
monotherapy with CCB or ARB therapy were 
initiated on AML/OM 5/20 mg and up-titrated 
every 4 weeks to AML/OM 5/40 mg, AML/OM 
10/40 mg, AML/OM 10/40 + HCTZ 12.5 mg, and 
AML/OM 10/40 + HCTZ 25 mg. Patients were 
up-titrated to a higher AML/OM dose if mean 
seated cuff BP (SeBP) was ≥120/70 mmHg, and 
up-titrated to any HCTZ dose if mean SeBP was 
≥125/75 mmHg. The primary efficacy endpoint 
was the cumulative proportion of patients 
achieving a seated cuff systolic BP (SeSBP) goal 
of <140 mmHg (<130 mmHg for patients with 
diabetes) after 12 weeks. Secondary endpoints 
included mean change from baseline in SeBP 
and ambulatory BP, ambulatory BP target 
achievement, and safety. 
Results: For the prior CCB (n = 118; baseline 
SeBP: 153.4/91.5 mmHg) and ARB (n = 237; 
154.6/92.6 mmHg) groups, SeSBP goal 
achievement after 12 weeks was 72.7% and 
76.9%, respectively. Mean changes (± SE) 
from baseline in SeBP were dose proportional
for prior CCB and ARB patients, ranging
from –9.9 (± 1.25)/–5.8 (± 0.83) mmHg and 
–13.9 (± 0.79)/–7.6 (± 0.47) mmHg at the 
AML/OM 5/20 mg dose, respectively, to –21.8 
(± 1.68)/–11.6 (± 1.12) mmHg and –26.2 
(± 1.31)/–15.0 (± 0.86) mmHg at the AML/OM 
10/40 mg + HCTZ 25 mg dose (P < 0.0001 for all). 
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Conclusion: An AML/OM-based titration 
regimen was efficacious in achieving BP goal 
in patients uncontrolled on prior monotherapy 
with a CCB or ARB. 
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INTRODUCTION
Hypertension is a prevalent condition that if 
left uncontrolled can increase cardiovascular 
morbidity and mortality as manifested by 
increased incidence of ischemic heart disease 
and stroke [1]. For many patients, achievement 
of blood pressure (BP) control requires escalation 
of monotherapy to combination therapy 
with agents from multiple pharmacological 
classes [2, 3]. Despite the recommendations 
of clinical practice guidelines, only 48.4% of 
patients have their hypertension controlled by 
treatment [4]. 
The Blood Pressure Control in All Subgroups 
With Hypertension (BP-CRUSH) study 
(ClinicalTrials.gov identifier: NCT00791258) 
evaluated improvement in BP goal achievement 
after patients who were uncontrolled on prior 
antihypertensive monotherapy were switched 
to a fixed-dose of amlodipine/olmesartan 
medoxomil (AML/OM), with or without 
hydrochlorothiazide (HCTZ), combination 
treatment regimen [5]. Fixed-dose combination 
therapy is one proven strategy to escalate therapy 
in patients who have hypertension uncontrolled 
by a single agent alone. In one study of
45 Canadian family practice sites, a simplified 
approach to hypertension treatment employing 
fixed-dose combination therapy was compared 
against treatment as usual, which resulted in 
significantly improved BP control of 64.7% 
versus 52.7%, respectively (P = 0.026) [6]. Fixed-
dose combination therapy also has the added 
benefit of improving adherence [7] and long-
term savings for the healthcare system, despite 
potentially higher out-of-pocket costs [8]. 
The purpose of this secondary analysis is 
to present the BP goal achievement rates, BP 
reductions, and safety findings of study patients 
in the primary BP-CRUSH study who did not 
achieve BP control with prior calcium channel 
blocker (CCB) or angiotensin II receptor blocker 
(ARB) monotherapy at baseline, and who were 
subsequently escalated to AML/OM ± HCTZ 
fixed-dose combination therapy. 
MATERIALS AND METHODS
Study Design
The BP-CRUSH study was a 20-week, prospective, 
open-label, multicenter, phase 4 (3b in South 
Africa) study in 999 patients with hypertension. 
Complete inclusion and exclusion criteria have 
been published previously [5]. Briefly, patients 
18–80 years of age were eligible to enter the 
study if their mean seated cuff systolic BP (SeSBP) 
was ≥140 mmHg (or ≥130 mmHg in patients 
with diabetes mellitus) and ≤180 mmHg, and 
their mean seated cuff diastolic BP (SeDBP) 
was ≤110 mmHg after at least 1 month of 
antihypertensive monotherapy. Patients 
uncontrolled on multiple antihypertensive 
therapies (including fixed-dose combination 
therapy, except for triamterene/HCTZ); with 
type 1 or 2 diabetes mellitus requiring insulin; 
type 2 diabetes mellitus and hemoglobin 
A1c (HbA1c) ≥9.0% at screening, and serum 
creatinine levels >2.0 mg/dL or calculated 
glomerular filtration rate <40 mL/min at 
screening; significant cardiac disease; or serious 
systemic diseases or secondary hypertension, 
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as well as pregnant or lactating women, were 
excluded. The cohorts of patients who were 
uncontrolled on prior monotherapy with a CCB 
or ARB were included in this secondary analysis. 
Patients provided signed informed consent 
before participating in any study procedures. 
The study protocol, amendment, informed 
consent forms, and information sheets were 
approved by the appropriate Independent Ethics 
Committees or Institutional Review Boards. The 
study was conducted in compliance with the 
Declaration of Helsinki and in accordance with 
the International Conference on Harmonization 
E6 Guideline for Good Clinical Practice (GCP), 
and United States Food and Drug Administration 
GCP guidelines.
Figure 1 shows the BP-CRUSH study design. 
After eligibility was determined, patients were 
switched from prior monotherapy to fixed-dose 
AML/OM 5/20 mg for 4 weeks. Patients were 
up-titrated to higher doses at 4-week intervals 
on the following schedule: AML/OM 5/40 mg, 
AML/OM 10/40 mg, AML/OM 10/40 mg + 
HCTZ 12.5 mg, and AML/OM 10/40 mg + HCTZ 
25 mg. Up-titration of dose was dependent on 
mean seated cuff BP (SeBP) measurements taken 
at treatment visits using an Omron® HEM-705CP 
automated BP monitor (Omron Corporation, 
Kyoto-Shi Kyoto, Japan). The mean of three 
SeBP measurements was used to determine if 
up-titration was necessary.
Patients were up-titrated to higher dosages 
of AML/OM if their mean SeSBP was ≥120 and 
<200 mmHg, or their mean SeDBP was ≥70 
and <115 mmHg. Patients were up-titrated to 
any HCTZ-containing dose if their mean SeSBP 
was ≥125 and <200 mmHg and/or mean SeDBP 
was ≥75 and <115 mmHg. Patients whose BP 
was controlled at the end of a 4-week interval 
(BP <120/70 mmHg for AML/OM doses or 
<125/75 mmHg for HCTZ-containing doses) 
remained at the same dose until the end of the 
study, or until their BP became uncontrolled 
(systolic BP [SBP] ≥130 mmHg or diastolic 
BP [DBP] ≥80 mmHg). If their BP became 
uncontrolled, patients were up-titrated to the 
next dosage in the treatment algorithm.
Efficacy Assessments
The primary efficacy endpoint was the cumulative 
proportion of patients achieving the SeSBP goal 
of <140 mmHg (or <130 mmHg in patients 






















Fig. 1  Study design. ABPM ambulatory blood pressure monitoring, AML amlodipine, HCTZ hydrochlorothiazide, 
OM olmesartan medoxomil. a Scheduled ABPM measurement for ABPM cohort
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Secondary efficacy endpoints included a 
cumulative SeBP goal of <140/90 mmHg (or 
<130/80 mmHg in patients with diabetes) at 
weeks 12 and 20, the reduction from baseline 
(last observation carried forward [LOCF]) in 
mean SeBP by titration dose, the cumulative 
SeBP goal of <140/90 mmHg by titration dose, 
the change from baseline in mean ambulatory 
BP at weeks 12 and 20 over 24 hours, daytime 
(8 AM–4 PM), nighttime (10 PM–6 AM), and during 
the last 2, 4, and 6 hours of the dosing interval, 
and the proportions of patients achieving mean 
24-hour, daytime, and nighttime ambulatory BP 
targets after 12 and 20 weeks of treatment. 
Safety Assessments
Safety variables measured included adverse 
events, laboratory parameters, vital signs, and 
physical examinations. Adverse events were 
collected and reported from the time of entry 
into the study for up to 14 days after the last 
dose of the study drug. An assessment of the 
severity of adverse events was made, as was a 
determination of causality with respect to study 
treatment.
Statistical Analysis
Demographics and baseline characteristics of 
the study population were summarized using 
descriptive statistics. The cumulative BP goal 
achievement rate was defined as the number 
of patients achieving BP goal at any time from 
the first dose date until the end of the period of 
interest (i.e., specified week or dosage) divided 
by the total number of patients having a post-
baseline BP measurement for the same period 
of interest. Changes in SeBP and ambulatory BP 
from baseline were summarized by titration dose 
(LOCF) and by visit without the LOCF method, 
and with descriptive statistics, and analyzed by 
a one-sample paired t-test with corresponding 
standard errors and 95% CIs. For measurements 
that employed LOCF, the last post-baseline 
measurement within a treatment period was 
carried forward to the end of that same period 
before being used in the analysis. 
RESULTS
Baseline Demographics
A total of 999 patients were enrolled into 
the primary study wherein 118 patients had 
uncontrolled BP on prior CCB monotherapy 
and 237 patients had uncontrolled BP on prior 
ARB monotherapy. Table 1 shows the baseline 
demographics of the two subgroups of interest. 
The mean age of patients in this subanalysis was 
54.9 years in the prior CCB group and 55.5 years 
in the prior ARB group, with 20.3% and 23.6% 
of patients aged 65 years or older, respectively. 
The prior CCB group had more female patients 
(59.3%) compared with the prior ARB group 
(39.2%). Patients in both cohorts had a body 
mass index in the obese range of approximately 
31 kg/m2. The majority of patients in the prior 
ARB group were Caucasian (69.6%), whereas 
only 48.3% were Caucasian in the prior CCB 
group, with the main difference being that the 
proportion of Black patients in the prior ARB 
group was less than one-half of that reported 
in the prior CCB group (15.2% vs. 35.6%, 
respectively). There were more patients with 
type 2 diabetes and slightly less patients with 
metabolic syndrome in the prior ARB treatment 
group compared with the prior CCB group.
Mean (± SD) baseline SeBP was 153.4 
(± 9.3)/91.5 (± 7.9) mmHg in the prior CCB 
group compared with 154.6 (± 9.2)/92.6 (± 8.4) 
mmHg in the prior ARB group. Mean (± SD) 
24-hour ambulatory BP was 133.6 (± 6.9)/80.7 
(± 7.2) mmHg in the prior CCB group (n = 23) 
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compared with 136.2 (± 12.3)/81.5 (± 9.0) mmHg 
in the prior ARB group (n = 84). In the prior CCB 
group, 75.5% of patients were up-titrated to the 
maximal dose of AML/OM 10/40 mg + HCTZ 
25 mg daily. By comparison, 69.7% were titrated 
to the maximal dose in the prior ARB group.
A breakdown of prior antihypertensive 
therapy in the prior CCB and prior ARB groups 
by specific drug showed that most patients 
in the prior CCB group had been previously 
taking AML monotherapy (n = 93; 78.8%). 
The other CCBs used as prior monotherapy 
included nifedipine, nisoldipine, isradipine, and 
felodipine. The most widely used ARBs in the 
prior ARB monotherapy group were valsartan 
(n = 79; 33.3%) and losartan (n = 43; 18.1%), 
and statistical analyses were performed for these 
two ARBs; however, analyses were not performed 
for the other ARBs used as prior monotherapy, 
which included telmisartan, irbesartan, and 
candesartan, because of the small numbers of 
patients in these subgroups.
Table 1  Demographics and baseline characteristics
Characteristic Prior CCB Prior ARB
  (n = 118) (n = 237)
Age, years, mean (± SD) 54.9 (11.6) 55.5 (11.3)
 Age ≥65 years, n (%) 24 (20.3) 56 (23.6)
Female, n (%) 70 (59.3) 93 (39.2)
Weight, kg, mean (± SD) 86.0 (17.0) 91.5 (22.7)
Body mass index, kg/m2, mean (± SD) 30.9 (5.3) 31.3 (6.3)
Race, n (%)
 Caucasian 57 (48.3) 165 (69.6)
 Black 42 (35.6) 36 (15.2)
 Asian 19 (16.1) 34 (14.3)
 American Indian/Alaskan Native 0 (0.0) 2 (0.8)
Ethnicity, n (%)
 Hispanic/Latino 1 (0.8) 37 (15.6)
Type 2 diabetes mellitus, n (%) 17 (14.4) 47 (19.8)
Metabolic syndrome, n (%) 57 (48.3) 108 (45.6)
Glucose, mg/dL, mean (± SD) 103.3 (18.9) 104.7 (21.6)
High-density lipoprotein, mg/dL, mean (± SD) 51.8 (15.6) 53.2 (16.8)
Triglycerides, mg/dL, mean (± SD) 153.0 (89.9) 157.0 (93.1)
SeBP, mmHg, mean (± SD) 153.4 (9.3)/91.5 (7.9) 154.6 (9.2)/92.6 (8.4)
ABPM subgroup, n 23 84
 24-hour ambulatory BP, mmHg, mean (± SD) 133.6 (6.9)/80.7 (7.2) 136.2 (12.3)/81.5 (9.0)
Prior antihypertensive therapy agent, n (%)a
  Losartan – 43 (18.1)
  Valsartan – 79 (33.3)
  Amlodipine 93 (78.8) –
ABPM ambulatory BP monitoring, ARB angiotensin II receptor blocker, BP blood pressure, CCB calcium channel blocker, 
SD standard deviation, SeBP seated cuff BP
a Only ARBs and CCBs for which ≥30 patients had received prior monotherapy with one of these agents are included, as the 
n-values <30 were considered to be too small to perform statistical analyses
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SeBP
Figure 2 shows the SeSBP goal achievement rates 
by week 12 for the two subgroups of interest. 
The majority of patients achieved an SeSBP of 
<140 mmHg (or <130 mmHg in patients with 
diabetes) in both prior therapy groups, with 4.2% 
fewer patients in the prior CCB group achieving 
this goal compared with the prior ARB group. 
For comparison, 76.2% and 77.9% of patients 
specifically taking prior ARB monotherapy with 
losartan or valsartan, respectively, achieved this 
same SeSBP goal. A cumulative SeBP goal of 
<140/90 mmHg (or <130/80 mmHg in patients 
with diabetes) was achieved in 65.8% and 83.8% 
of patients in the prior CCB group by weeks 12 
and 20, respectively. In the prior ARB group, 
cumulative SeBP goal achievement was 72.2% 
and 86.8% by weeks 12 and 20, respectively. 
The proportions of patients achieving the 
SeBP threshold of <140/90 mmHg in the prior 
CCB and prior ARB subgroups at the highest 
dual-combination therapy (AML/OM 10/40 mg) 
and triple-combination therapy (AML/OM 
10/40 mg + HCTZ 25 mg) doses are shown 
in Figure 3. A greater proportion of patients 
achieved this threshold in the prior ARB group 
at both titration doses compared with the prior 
CCB group. 
Figure 4 shows the proportion of patients 
achieving the SeBP threshold of <140/90 mmHg 
at the highest dual-combination therapy (AML/
OM 10/40 mg) and triple-combination therapy 
(AML/OM 10/40 mg + HCTZ 25 mg) doses for 
the prior ARB monotherapy losartan (n = 41) 
and valsartan (n = 76) subgroups. SeBP goal 
achievement was similar between prior losartan 
and valsartan monotherapy subgroups at the 
AML/OM 10/40 mg dose; however, a greater 
proportion of patients in the prior losartan 
group achieved the SeBP goal compared with 
the prior valsartan subgroup at the AML/OM 
10/40 mg + HCTZ 25 mg dose.
Mean SeSBP was significantly reduced from 
baseline at the week 12 and week 20 visits in the 
prior CCB (18.3 and 23.4 mmHg, respectively; both 
P < 0.0001) and prior ARB (23.7 and 28.5 mmHg, 
respectively; both P < 0.0001) subgroups. Figure 5 
shows the mean (± SE) decrease from baseline 
in SeBP by titration dose (LOCF). At all titration 
steps, SeBP was significantly reduced from 
baseline (P < 0.0001) in both the prior CCB and 
prior ARB groups. A mean (± SE) change in SeBP 
(LOCF) of –17.9 (± 1.27)/–9.7 (± 0.75) mmHg from 
a baseline SeBP of 153.9/91.7 mmHg was observed 
in the prior CCB group at the end of the AML/OM 
10/40 mg dose period. The change from baseline 
in the prior ARB group was –22.3 (± 0.92)/–12.3 
(± 0.55) mmHg from a baseline SeBP of 155.4/93.3 
mmHg. The mean (± SE) change in SeBP (LOCF) 
after treatment with the maximally titrated dose 
of AML/OM 10/40 mg + HCTZ 25 mg was –21.8 
(± 1.68)/–11.6 (± 1.12) mmHg from a baseline 
SeBP of 154.4/92.3 mmHg in the prior CCB group, 
compared with –26.2 (± 1.31)/–15.0 (± 0.86) mmHg 






























Fig. 2  The proportion of patients achieving the SeSBP 
goal of <140 mmHg (or <130 mmHg for patients with 
diabetes) in the prior CCB and prior ARB subgroups. 
ARB angiotensin II receptor blocker, CCB calcium channel 
blocker, SeSBP seated cuff systolic blood pressure. 
a The majority (80%) of patients in the prior CCB 
subgroup had been taking amlodipine monotherapy
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prior ARB group. Results for the prior losartan 
and valsartan subgroups were similar to those 
observed for the prior ARB monotherapy group, 
with SeBP reductions generally being greater 
overall for losartan compared with valsartan 
across the AML/OM ± HCTZ titration regimen. 
Mean (± SE) SeBP reductions ranged from 18.5 
(± 1.9)/9.5 (± 1.3) mmHg to 28.3 (± 3.3)/18.7 
(± 1.9) mmHg for prior losartan and 13.4 
(± 1.4)/7.4 (± 0.8) mmHg to 25.2 (± 2.2)/13.2 
(± 1.3) mmHg for prior valsartan monotherapy. 
At all titration steps, SeBP was significantly 
69.0
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Prior ARB Prior CCB Prior ARB
Fig. 3  The proportions of patients achieving the SeBP threshold of <140/90 mmHg in the prior CCB and prior 
ARB subgroups at the highest dual-combination therapy (AML/OM 10/40 mg) and triple-combination therapy 
(AML/OM 10/40 mg + HCTZ 25 mg) doses. AML amlodipine, ARB angiotensin II receptor blocker, CCB calcium 
channel blocker, HCTZ hydrochlorothiazide, OM olmesartan medoxomil, SeBP seated cuff blood pressure
75.6
AML/OM 10/40 mg AML/OM 10/40 mg





































Prior VAL Prior LOS Prior VAL
Fig. 4  The proportions of patients achieving the SeBP threshold of <140/90 mmHg in the prior angiotensin II receptor 
blocker subgroups by agent (LOS and VAL) at the highest dual-combination therapy (AML/OM 10/40 mg) and triple-
combination therapy (AML/OM 10/40 mg + HCTZ 25 mg) doses. AML amlodipine, HCTZ hydrochlorothiazide, LOS 
losartan, OM olmesartan medoxomil, SeBP seated cuff blood pressure, VAL valsartan
















































All changes P < 0.0001 versus baseline
Baseline SeBP

































































All changes P < 0.0001 versus baseline
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Fig. 5  Change from baseline in mean (± SE) SeBP by titration dose (last observation carried forward) in the (a) prior 
calcium channel blocker, (b) prior angiotensin II receptor blocker, (c) prior losartan, and (d) prior valsartan subgroups. 
AML amlodipine, HCTZ hydrochlorothiazide, OM olmesartan medoxomil, SeBP seated cuff blood pressure, SeDBP seated 
cuff diastolic blood pressure, SeSBP seated cuff systolic blood pressure

















































All changes P < 0.0001 versus baseline
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All changes P < 0.0001 versus baseline
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Fig. 5  continued
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reduced from baseline (P < 0.0001) in both the 
prior valsartan and prior losartan groups.
24-Hour Ambulatory BP Monitoring
Figure 6 shows the change from baseline 
in mean 24-hour, daytime, and nighttime 
ambulatory BP through weeks 12 and 
20. By week 12, the mean (± SE) 24-hour 
change from baseline in ambulatory BP was 
–11.1 (± 1.91)/–6.9 (± 1.41) mmHg from a 
baseline BP of 134.1/79.8 mmHg in the prior 
CCB group, compared with –16.4 (± 1.43)/
–10.1 (± 0.85) mmHg from a baseline BP 
of 137.4/82.8 mmHg in the prior ARB 
group. At week 20, the mean (± SE) 24-hour 
change from baseline in ambulatory BP was 
–19.9 (± 2.72)/–13.5 (± 2.04) mmHg from a 
baseline BP of 135.3/83.0 mmHg in the prior 
CCB group, compared with –21.3 (± 1.63)/
–13.2 (± 0.92) mmHg from a baseline BP of 
136.4/81.7 mmHg in the prior ARB group.
Figure 7 shows ambulatory BP monitoring 
(ABPM) target achievement rates by weeks 12 
and 20 by subgroup for the 24-hour, daytime, 
and nighttime ABPM targets of <130/80 mmHg, 
<135/85 mmHg, and <120/70 mmHg, 
respectively. ABPM target achievement rates by 
week 12 in the prior CCB group were 64.7%, 
64.7%, and 47.1%, respectively. By comparison, 
target achievement rates in the prior ARB group 
were higher at 81.5%, 78.5%, and 60.0%, 
respectively. Target achievement rates by week 
20 in the prior CCB group were 84.6%, 92.3%, 
and 84.6% compared with 91.5%, 88.1%, and 
79.7% in the prior ARB group. 
Mean (± SE) changes in ambulatory SBP 
and DBP in the last 2, 4, and 6 hours of the 
dosing interval were all significantly decreased 
from baseline at week 12 in the prior CCB 
(10.6 [2.88]/5.7 [2.31] mmHg, 11.5 [2.85]/
6.9 [2.14] mmHg, and 10.6 [2.70]/6.6 [1.99] 
mmHg, respectively; all P < 0.05 vs. baseline)
and prior ARB (16.3 [2.03]/9.4 [1.32] mmHg, 
15.0 [1.75]/8.7 [1.19] mmHg, and 14.8 
[1.65]/8.5 [1.11] mmHg, respectively; all P < 
0.0001 vs. baseline) treatment groups. Mean 
(± SE) changes in ambulatory SBP and DBP in 
the last 2, 4, and 6 hours of the dosing interval 
were also all significantly decreased from 
baseline at week 20 in the prior CCB (20.9 
[3.14]/14.1 [1.61] mmHg, 19.5 [2.77]/13.0 [2.04] 
mmHg, and 18.9 [2.69]/13.3 [2.19] mmHg, 
respectively; all P < 0.0001 vs. baseline) and 
prior ARB (20.2 [2.17]/12.3 [1.37] mmHg, 
17.4 [2.00]/10.7 [1.28] mmHg, and 17.4 
[1.87]/10.6 [1.21] mmHg, respectively; all 
P < 0.0001 vs. baseline). For all ambulatory BP 
time points at week 12, ambulatory SBP and DBP 
reductions were greater in prior ARB patients 
compared with prior CCB patients for the 2-, 4-, 
and 6-hour time points at week 12 and week 20.
Safety and Tolerability
Table 2 highlights the incidence of adverse 
events in the study population. A total of 55.1% 
of patients in the prior CCB group experienced 
a treatment-emergent adverse event (TEAE) 
compared with 45.6% of patients in the prior 
ARB group. The majority of TEAEs were mild-to-
moderate in intensity in both subgroups. Serious 
TEAEs occurred in 0.8% of patients in the prior 
CCB group compared with 2.1% of patients in 
the prior ARB group. TEAEs judged to be drug-
related occurred in 23.7% of patients in the prior 
CCB group compared with 21.1% of patients in 
the prior ARB group. TEAEs that led to study 
discontinuation occurred in 3.4% of patients in 
the prior CCB group compared with 6.8% in the 
prior ARB group. 
Drug-related TEAEs that led to study 
discontinuation occurred in 3.4% of patients 
in the prior CCB group and 5.1% in the prior 
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Fig. 6  Change from baseline in the prior CCB and prior ARB subgroups in mean (± SE) 24-hour, daytime, and nighttime 
ambulatory BP at (a) week 12 and (b) week 20. ARB angiotensin II receptor blocker, BP blood pressure, CCB calcium 
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ARB group. Table 3 shows the most commonly 
reported drug-related TEAEs by titration dose and 
by total for each subgroup. The most frequently 
reported drug-related TEAEs were dizziness, 
peripheral edema, hypotension, nausea, fatigue, 
and muscle spasms. The most frequently 
reported drug-related TEAE in both the prior 
CCB and prior ARB groups was peripheral edema 
at a total rate of 4.2% and 6.8%, respectively. 
The highest incidence of drug-related peripheral 
edema was observed at the maximum AML/OM 
10/40 mg dose in both the prior CCB (2.0%) and 
prior ARB (5.0%) groups. When HCTZ 12.5 mg 
and 25 mg were added on to AML/OM, overall 
rates of drug-related peripheral edema decreased 
from 3.4% to 1.1% and from 5.9% to 1.1% in the 
prior CCB and prior ARB groups, respectively. 
There were no adverse events leading to death 
in the BP-CRUSH study.
DISCUSSION
Uncontrolled hypertension has implications for 



























































































Fig. 7  Mean 24-hour, daytime, and nighttime ambulatory BP target achievement rates in the prior CCB and prior ARB 
subgroups at (a) week 12 and (b) week 20. ARB angiotensin II receptor blocker, BP blood pressure, CCB calcium channel 
blocker
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morbidity and mortality, as well as for the 
healthcare system as a whole with regards 
to the cost of medical care for patients with 
hypertension-associated target organ damage. The 
AML/OM ± HCTZ titration regimen employed in 
the primary BP-CRUSH study was an effective 
means of enabling patients with uncontrolled 
BP on prior monotherapy with angiotensin-
converting enzyme inhibitors or ARBs to reach 
the primary endpoint of SeSBP <140 mmHg (or 
<130 mmHg in patients with diabetes).
The SeSBP goal at week 12 and SeBP 
goal achievement at weeks 12 and 20 were 
consistently higher in the prior ARB group 
relative to the prior CCB group. This higher rate 
of achievement was noted despite the slightly 
Table 2  Summary of adverse events 
Adverse event, n (%) Prior CCB  Prior ARB
 (n = 118) (n = 237)
TEAEs 65 (55.1) 108 (45.6)
Drug-related TEAEs 28 (23.7) 50 (21.1)
Serious TEAEs 1 (0.8) 5 (2.1)
TEAEs leading to discontinuation 4 (3.4) 16 (6.8)
Most commonly reported drug-related TEAEs
Dizziness 4 (3.4) 15 (6.3)
Peripheral edema 5 (4.2) 16 (6.8)
Hypotension 3 (2.5) 3 (1.3)
Nausea 3 (2.5) 1 (0.4)
Fatigue 1 (0.8) 7 (3.0)
Muscle spasms 3 (2.5) 2 (0.8)
ARB angiotensin II receptor blocker, CCB calcium channel 
blocker, TEAE treatment-emergent adverse event
Table 3  DR-TEAEs by titration dose occurring at an incidence of ≥2%
  AML/OM AML/OM AML/OM AML/OM AML/OM 
  5/20 mg 5/40 mg 10/40 mg 10/40 mg +  10/40 mg +  
     HCTZ 12.5 mg HCTZ 25 mg
Prior CCB group
Patients exposed to  
the dose, n 118 109 101 94 71
Discontinuation from dose  
due to a DR-TEAE, n (%) 1 (0.8) 0 (0.0) 1 (1.0) 2 (2.1) 0 (0.0)
TEAE, n (%)
 Dizziness 3 (2.5) 0 (0.0) 0 (0.0) 1 (1.1) 0 (0.0)
 Peripheral edema 1 (0.8) 1 (0.9) 2 (2.0) 1 (1.1) 0 (0.0)
 Nausea 2 (1.7) 0 (0.0) 0 (0.0) 1 (1.1) 0 (0.0)
 Syncope 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.1) 0 (0.0)
Prior ARB group
Patients exposed to the  
dose, n 237 219 199 175 122
Discontinuation from dose  
due to a DR-TEAE, n (%) 2 (0.8) 2 (0.9) 3 (1.5) 2 (1.1) 3 (2.5)
TEAE, n (%)
 Dizziness 4 (1.7) 2 (0.9) 4 (2.0) 6 (3.4) 2 (1.6)
 Peripheral edema 2 (0.8) 2 (0.9) 10 (5.0) 1 (0.6) 1 (0.8)
 Hypotension 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (2.5)
AML amlodipine, ARB angiotensin II receptor blocker, CCB calcium channel blocker, DR drug related, 
HCTZ hydrochlorothiazide, OM olmesartan medoxomil, TEAE treatment-emergent adverse event
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higher baseline mean SeBP observed in the 
prior ARB group. The SeSBP goal achievement 
rate in this substudy was slightly higher in the 
prior ARB group relative to goal achievement in 
the total cohort (n = 999) of the primary study 
(76.9% vs. 75.8%, respectively) and slightly 
lower in the prior CCB group (72.7% vs. 75.8%). 
CCBs and ARBs have different mechanisms 
of action and, thus, it might be expected that 
goal achievement rates would not be identical. 
A larger study designed to test the efficacy of a 
regimen that adds on an agent to an existing 
class of medication versus switching to a 
different agent when escalating to combination 
therapy would be required to determine if there 
is any difference between the two approaches 
to therapy. It is noteworthy that previously 
published data from this study demonstrated 
that 69.3% and 73.1% of patients who had BP 
uncontrolled on prior angiotensin-converting 
enzyme inhibitor monotherapy achieved SeSBP/
SeDBP and SeSBP goals, respectively, by week 12, 
and 83.0% had achieved SeSBP/SeDBP goal by 
week 20 [5]. These results compare favorably 
with patients in both the prior CCB and prior 
ARB monotherapy groups. 
The same higher trend in the prior ARB group 
relative to the prior CCB group was noted in 
the change from baseline in mean SeBP and in 
mean 24-hour ambulatory BP (except for DBP 
at week 20). The prior ARB group was observed 
to have a greater reduction in SeBP compared 
with the prior CCB group by 4.4/2.6 mmHg 
and by 4.4/3.4 mmHg after titration to, and 
treatment with, AML/OM 10/40 mg and AML/
OM 10/40 mg + HCTZ 25 mg, respectively. 
Compared with the prior CCB group, the prior 
ARB group had a higher reduction in mean 
24-hour ambulatory SBP/DBP by 5.3/3.2 mmHg 
at week 12, and in mean 24-hour ambulatory 
SBP of 1.4 mmHg at week 20. Regardless of these 
differences in BP reduction, patients from both 
treatment groups had significantly reduced SeBP 
and ambulatory BP from baseline when switched 
to an AML/OM regimen, with or without HCTZ.
The achievement of American Heart 
Association-recommended ambulatory BP 
targets followed an overall consistent pattern 
as was observed for the achievement of SeBP 
goals, and the current titration regimen enabled 
a majority of patients in both cohorts to achieve 
these targets. By week 12, the prior ARB group 
had substantially higher achievement rates for 
the mean 24-hour BP target of <130/80 mmHg, 
mean daytime target of <135/85 mmHg, and 
mean nighttime target of <120/70 mmHg 
compared with the prior CCB group. However, 
at week 20, the prior ARB group had a higher 
rate of achievement for the mean 24-hour BP 
target, whereas the prior CCB group had higher 
rates of achievement for both the daytime and 
nighttime BP targets. 
The AML/OM titration regimen was well 
tolerated overall in both subgroups. The 
incidence of TEAEs and drug-related TEAEs were 
higher in the prior CCB group compared with 
the prior ARB group, whereas the incidence of 
drug-related TEAEs leading to discontinuation 
were lower in the prior CCB group compared 
with the prior ARB group. Rates of peripheral 
edema were highest in the prior CCB and ARB 
groups at a dose of AML/OM 10/40 mg daily. The 
addition of HCTZ 12.5 mg and 25 mg to AML/
OM decreased the incidence of peripheral edema 
in both the prior CCB and prior ARB groups. 
These findings provide additional support to 
previous observations that the addition of a 
thiazide diuretic to a regimen containing high-
dose AML can help to mitigate the incidence of 
edema [5, 9].
A limitation of this study is its open-label, 
single-arm design, which could potentially 
introduce treatment bias due to lack of blinding. 
Another limitation is that patients who volunteer 
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to participate in clinical studies are likely to have 
better adherence to treatment than patients in 
the general population, potentially increasing 
the BP goal achievement rates compared with 
those observed in clinical practice. The strengths 
of the BP-CRUSH study include the large study 
population, the utilization of ABPM to assess 
24-hour BP control, and the use of aggressive BP 
criteria for dose titration.
In conclusion, an AML/OM-based titration 
regimen enabled the achievement of BP 
control in patients not achieving guideline-
recommended goals with prior CCB or ARB 
monotherapy. The switching of patients 
with uncontrolled BP on prior CCB or ARB 
monotherapy to a fixed-dose titration regimen 
of AML/OM, with or without HCTZ, did not 
impact the achievement of the primary outcome 
in this substudy. A large proportion of patients 
in both subgroups achieved SeBP goals regardless 
of baseline monotherapy, and these high rates 
of BP control were associated with significant 
reductions in both SeBP and ambulatory BP. 
Data from this study demonstrate that the 
treat-to-target BP approach employed in the 
BP-CRUSH study could be potentially beneficial 
in overcoming clinical inertia in daily practice. 
Simple changes to treatment in the clinical 
environment, such as mandatory up-titration 
and the addition of other antihypertensive 
agents if BP goals are not achieved, can translate 
into real-world benefits in overcoming clinical 
inertia and improving BP control.
ACKNOWLEDGMENTS
This study was supported by Daiichi Sankyo, 
Inc. Medical writing and editorial services were 
provided by Robert Schupp, PharmD, and Alan 
J. Klopp, PhD, of inScience Communications, 
Springer Healthcare. Support for this assistance was 
funded by Daiichi Sankyo, Inc. Dr. Neutel is the 
guarantor for this article, and takes responsibility 
for the integrity of the work as a whole.
Conflict of Interest. Joel Neutel serves as 
a consultant for Novartis and has received 
payment for lectures, including services on the 
speaker’s bureau for Takeda, the Bristol-Myers 
Squibb/Sanofi Pharmaceutical Partnership, 
Novartis, Pfizer Inc., Boehringer Ingelheim, 
Forest Laboratories, Merck, and Daiichi Sankyo, 
Inc. Ali Shojaee and Jen-Fue Maa are employees 
of Daiichi Sankyo, Inc.
Open Access. This article is distributed 
under the terms of the Creative Commons 
Attribution Noncommercial License which 
permits any noncommercial use, distribution, 
and reproduction in any medium, provided the 
original author(s) and source are credited.
REFERENCES 
1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins 
R; Prospective Studies Collaboration. Age-specific 
relevance of usual blood pressure to vascular 
mortality: a meta-analysis of individual data for 
one million adults in 61 prospective studies. 
Lancet. 2002;360:1903–13.
2. ALLHAT Officers and Coordinators for the ALLHAT 
Collaborative Research Group. Major outcomes 
in high-risk hypertensive patients randomized to 
angiotensin-converting enzyme inhibitor or calcium 
channel blocker vs diuretic: The Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart 
Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.
3. Tedesco MA, Natale F, Calabro R. Effects of 
monotherapy and combination therapy on blood 
pressure control and target organ damage: a 
randomized prospective intervention study in a 
large population of hypertensive patients. J Clin 
Hypertens (Greenwich). 2006;8:634–41.
4. Yoon SS, Ostchega Y, Louis T. Recent trends in the 
prevalence of high blood pressure and its treatment 
and control, 1999–2008. NCHS Data Brief. 2010:1–8.
5. Weir MR, Hsueh WA, Nesbitt SD, et al. A titrate-
to-goal study of switching patients uncontrolled 
on antihypertensive monotherapy to fixed-dose 
combinations of amlodipine and olmesartan 
medoxomil ± hydrochlorothiazide. J Clin 
Hypertens (Greenwich). 2011;13:404–12.
Adv Ther (2012)  29(6):508–523. 523
6. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, 
Nelson SA, Feagan BG. A simplified approach to 
the treatment of uncomplicated hypertension: a 
cluster randomized, controlled trial. Hypertension. 
2009;53:646–53.
7. Taylor AA, Shoheiber O. Adherence to 
antihypertensive therapy with fixed-dose 
amlodipine besylate/benazepril HCl versus 
comparable component-based therapy. Congest 
Heart Fail. 2003;9:324–32.
8. Rabbani A, Alexander GC. Out-of-pocket and total 
costs of fixed-dose combination antihypertensives 
and their components. Am J Hypertens. 
2008;21:509–13.
9. Chrysant SG, Melino M, Karki S, Lee J, Heyrman 
R. The combination of olmesartan medoxomil 
and amlodipine besylate in controlling high blood 
pressure: COACH, a randomized, double-blind, 
placebo-controlled, 8-week factorial efficacy and 
safety study. Clin Ther. 2008;30:587–604.
